{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T01:59:32Z","timestamp":1767664772016,"version":"3.40.1"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.vhri.2024.101051","type":"journal-article","created":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T23:18:16Z","timestamp":1730416696000},"page":"101051","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Cost-Utility Analysis of Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Chemotherapy Regimen in Comparison With Gemcitabine and Cisplatin Chemotherapy Regimen in the Treatment of Patients With Muscle Invasive Bladder Cancer in Iran"],"prefix":"10.1016","volume":"46","author":[{"given":"Sadra","family":"Nadimi Parashkouhi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iman","family":"Karimzadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alireza","family":"Rezvani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hadi","family":"Abbasian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leila","family":"Zarei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.vhri.2024.101051_bib2","first-page":"567","article-title":"Epidemiology and hospitalization cost of bladder cancer in Kerman Province, Southeastern Iran","volume":"47","author":"Rashidian","year":"2018","journal-title":"Iran J Public Health"},{"issue":"3","key":"10.1016\/j.vhri.2024.101051_bib3","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s00345-009-0395-z","article-title":"Economic aspects of bladder cancer: what are the benefits and costs?","volume":"27","author":"Sievert","year":"2009","journal-title":"World J Urol"},{"issue":"2","key":"10.1016\/j.vhri.2024.101051_bib4","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.eururo.2014.01.006","article-title":"The economics of bladder cancer: costs and considerations of caring for this disease","volume":"66","author":"Svatek","year":"2014","journal-title":"Eur Urol"},{"author":"Compare","key":"10.1016\/j.vhri.2024.101051_bib5"},{"issue":"1","key":"10.1016\/j.vhri.2024.101051_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12955-018-1077-6","article-title":"Quality of life in bladder cancer patients receiving medical oncological treatment; a systematic review of the literature","volume":"17","author":"Taarnh\u00f8j","year":"2019","journal-title":"Health Qual Life Outcomes"},{"author":"Joaquim Bellmunt","key":"10.1016\/j.vhri.2024.101051_bib8"},{"issue":"12","key":"10.1016\/j.vhri.2024.101051_bib9","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1093\/jjco\/hyaa123","article-title":"Effect of neoadjuvant chemotherapy on health-related quality of life in patients with muscle-invasive bladder cancer: results from JCOG0209, a randomized phase III study","volume":"50","author":"Kitamura","year":"2020","journal-title":"Jpn J Clin Oncol"},{"issue":"2","key":"10.1016\/j.vhri.2024.101051_bib10","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.eururo.2020.08.024","volume":"79","author":"Pfister","year":"2021","journal-title":"Eur Urol"},{"issue":"18","key":"10.1016\/j.vhri.2024.101051_bib11","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.21.02051","article-title":"Dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin or gemcitabine and cisplatin as perioperative chemotherapy for patients with nonmetastatic muscle-invasive bladder cancer: results of the GETUG-AFU V05 VESPER trial","volume":"40","author":"Pfister","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"23","key":"10.1016\/j.vhri.2024.101051_bib12","doi-asserted-by":"crossref","first-page":"5450","DOI":"10.1002\/cncr.24634","article-title":"Cost-effectiveness analysis of immediate radical cystectomy versus intravesical bacillus Calmette-Guerin therapy for high-risk, high-grade (T1G3) bladder cancer","volume":"115","author":"Kulkarni","year":"2009","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.vhri.2024.101051_bib13","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1634\/theoncologist.2017-0277","article-title":"Cost-effectiveness of Nivolumab in recurrent metastatic head and neck squamous cell carcinoma","volume":"23","author":"Zargar","year":"2018","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.vhri.2024.101051_bib14","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/COC.0b013e31817c6a4d","article-title":"A\u00a0Markov model assessing the effectiveness and cost-effectiveness of FOLFOX compared with FOLFIRI for the initial treatment of metastatic colorectal cancer","volume":"32","author":"Tumeh","year":"2009","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.vhri.2024.101051_bib15","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/01.mlr.0000156862.33341.45","article-title":"Utilities for prostate cancer health states in men aged 60 and older","author":"Stewart","year":"2005","journal-title":"Med Care"},{"issue":"3","key":"10.1016\/j.vhri.2024.101051_bib16","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.eururo.2021.09.018","article-title":"Health-related quality of life for patients undergoing radical cystectomy: results of a large prospective cohort","volume":"81","author":"Clements","year":"2022","journal-title":"Eur Urol"},{"issue":"10139","key":"10.1016\/j.vhri.2024.101051_bib17","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1016\/S0140-6736(18)30996-6","article-title":"Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label,andomizedd, phase 3, non-inferiority trial","volume":"391","author":"Parekh","year":"2018","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.vhri.2024.101051_bib21","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.3390\/cancers13112770","article-title":"Comparison of oncologic outcomes of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) with gemcitabine and cisplatin (GC) as neoadjuvant chemotherapy for muscle-invasive bladder cancer: systematic review and meta-analysis","volume":"13","author":"Chung","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.vhri.2024.101051_bib22","first-page":"e1","article-title":"An economic analysis comparing health care resource use and cost of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin versus gemcitabine and cisplatin as neoadjuvant therapy for muscle invasive bladder cancer","volume":"834","author":"Montazeri","year":"2021","journal-title":"Urol Oncol"},{"issue":"1","key":"10.1016\/j.vhri.2024.101051_bib23","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1586\/14737167.4.1.27","article-title":"Cost\u2013utility analysis of the GC versus MVAC regimens for the treatment of locally advanced or metastatic bladder cancer","volume":"4","author":"Robinson","year":"2004","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"24","key":"10.1016\/j.vhri.2024.101051_bib24","doi-asserted-by":"crossref","first-page":"4194","DOI":"10.1002\/cncr.34502","article-title":"Comparative cost-effectiveness of neoadjuvant chemotherapy regimens for muscle-invasive bladder cancer: results according to VESPER data","volume":"128","author":"Joyce","year":"2022","journal-title":"Cancer"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109924000840?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109924000840?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T03:04:41Z","timestamp":1742439881000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212109924000840"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":19,"alternative-id":["S2212109924000840"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2024.101051","relation":{},"ISSN":["2212-1099"],"issn-type":[{"type":"print","value":"2212-1099"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Utility Analysis of Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Chemotherapy Regimen in Comparison With Gemcitabine and Cisplatin Chemotherapy Regimen in the Treatment of Patients With Muscle Invasive Bladder Cancer in Iran","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2024.101051","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of International Society for Pharmacoeconomics and Outcomes Research, Inc.","name":"copyright","label":"Copyright"}],"article-number":"101051"}}